Comprehensive safety study confirms long-term safety of Curcugen supplementation


Preclinical study determines that long-term supplementation with Curcugen is safe.

Photo © COLOA Studio

Photo © COLOA Studio

A new preclinical study published in Biomedical Research International1 confirmed the long-term safety of Curcugen curcumin formulation (from Dolcas Biotech, LLC, based in Landing, NJ). The safety study used a standard series of in vitro and in vivo safety studies, in accordance with OECD guidelines, including the toxicological assessment of acute, oral, and 90-day repeated dosing.

Tests of acute oral toxicity on rats found a median lethal dose (LD50) of greater than 5,000mg/kg body weight of Curcugen. LD50 refers to the dose required to kill half the members of a test population after a specified test duration. Additionally, a sub chronic assessment of Curcugen, as administered to rats over 90 days, resulted in a no observed adverse effect level (NOAEL) at a dose of 2,000mg/kg body weight/day. Moreover, the extract did not elicit any genotoxic or clastogenic effect in genotoxicity tests.


  1. Nirvanashetty S et al. "Safety evaluation of oleoresi-based turmeric formulation: Assessment of genotoxicity and acute and subchronic oral toxicity." Biomedical Research International, Published online ahead of print on March 31, 2022,
Related Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.